Skip to main content

Welkom bij Erasmus MC & Bohn Stafleu van Loghum

Erasmus MC heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Registreer

Om ook buiten de locaties van Erasmus MC, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van Erasmus MC.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top
Gepubliceerd in:

01-04-2018 | Onderzoek

Medicinale cannabis

Eén van de behandelingsopties in de palliatieve zorg

Auteur: Maurice van der Vorst

Gepubliceerd in: Pallium | Uitgave 2/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Pijn, misselijkheid, slechte eetlust, gewichtsverlies en angst zijn veelvoorkomende klachten van patiënten in de palliatieve fase. Medicinale cannabis is één van de behandelingsopties om deze klachten te verminderen. De wetenschappelijke bewijsvoering voor het gebruik van deze middelen in de palliatieve zorg is echter vaak niet goed onderbouwd. In dit artikel bespreken we de werkzaamheid en bijwerkingen van medicinale cannabis bij gebruik in de palliatieve zorg nader.
Literatuur
1.
go back to reference World drug report. New York: United Nations, Office on Drugs and Crime; 2017. World drug report. New York: United Nations, Office on Drugs and Crime; 2017.
2.
go back to reference Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton (FL): CRC Press; 1986. p. 1-19. Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton (FL): CRC Press; 1986. p. 1-19.
3.
go back to reference Zhornitsky S, Potvin S. Cannabidiol in humans — The quest for therapeutic targets. Pharmaceuticals 2012; 5: 529-552. Zhornitsky S, Potvin S. Cannabidiol in humans — The quest for therapeutic targets. Pharmaceuticals 2012; 5: 529-552.
6.
go back to reference Grotenhermen F, Berger M, Gebhardt K. Cannabidiol. Solothurn: Nachtschatten; 2015. Grotenhermen F, Berger M, Gebhardt K. Cannabidiol. Solothurn: Nachtschatten; 2015.
7.
go back to reference Whiting PF, Wolff RF, Deshpande S et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015; 313: 2456-2473. Whiting PF, Wolff RF, Deshpande S et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015; 313: 2456-2473.
8.
go back to reference Mücke M, Carter C, Cuhls H et al. Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety. Schmerz. 2016; 30: 25-36. Mücke M, Carter C, Cuhls H et al. Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety. Schmerz. 2016; 30: 25-36.
9.
go back to reference Brisbois TD, de Kock IH, Watanabe SM et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011; 22: 2086-2093. Brisbois TD, de Kock IH, Watanabe SM et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011; 22: 2086-2093.
10.
go back to reference Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002; 20: 567–573. Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002; 20: 567–573.
11.
go back to reference Johnson JR, Burnell-Nugent M, Lossignol D et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010; 39: 167–179. Johnson JR, Burnell-Nugent M, Lossignol D et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010; 39: 167–179.
12.
go back to reference Portenoy RK, Ganae-Motan ED, Allende S et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012; 13: 438–449. Portenoy RK, Ganae-Motan ED, Allende S et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012; 13: 438–449.
13.
go back to reference Strasser F. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. 2006; J Clin Oncol 24: 3394–3400. Strasser F. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. 2006; J Clin Oncol 24: 3394–3400.
14.
go back to reference Abrams DI, Hilton JF, Leiser RJ et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003; 139: 258–266. Abrams DI, Hilton JF, Leiser RJ et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003; 139: 258–266.
15.
go back to reference Beal JE, Olson R, Laubenstein L et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. 1995; J Pain Symptom Manage 10: 89–97. Beal JE, Olson R, Laubenstein L et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. 1995; J Pain Symptom Manage 10: 89–97.
16.
go back to reference Timpone JG, Wright DJ, Li N et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses. 1997; 13: 305–315. Timpone JG, Wright DJ, Li N et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses. 1997; 13: 305–315.
17.
go back to reference Volicer L, Stelly M, Morris J et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry, 1997; 12 :913-919. Volicer L, Stelly M, Morris J et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry, 1997; 12 :913-919.
Metagegevens
Titel
Medicinale cannabis
Eén van de behandelingsopties in de palliatieve zorg
Auteur
Maurice van der Vorst
Publicatiedatum
01-04-2018
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Pallium / Uitgave 2/2018
Print ISSN: 1389-2630
Elektronisch ISSN: 1875-7049
DOI
https://doi.org/10.1007/s12479-018-0029-5